Elevation Oncology Says Cash, Cash Equivalents And Marketable Securities Of $104.1M As Of March 31, 2024, Plus $14.5M In Net Proceeds Raised Under Its ATM Facility Subsequent To Q1 Of 2024, To Be Sufficient To Fund Its Current Operations Into 2026
Elevation Oncology Says Cash, Cash Equivalents And Marketable Securities Of $104.1M As Of March 31, 2024, Plus $14.5M In Net Proceeds Raised Under Its ATM Facility Subsequent To Q1 Of 2024, To Be Sufficient To Fund Its Current Operations Into 2026
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.